Nashville, TNNCT07760961Now EnrollingIRB Ready

Postbariatric Hypoglycemia Clinical Trial in Nashville, TN

Access cutting-edge postbariatric hypoglycemia treatment through this phase 2 clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Vogenx, Inc.

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access postbariatric hypoglycemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related postbariatric hypoglycemia treatment provided free

Apply for This Nashville Location

Check if you qualify for this postbariatric hypoglycemia clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Postbariatric Hypoglycemia Study in Nashville

VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.

Sponsor: Vogenx, Inc.

Who Can Participate

Inclusion Criteria

Males and nonpregnant females, ages ≥18 years old, having had Roux-en-Y bariatric surgery more than 12 months prior to signing the ICF.
History of reactive hypoglycemia with Whipple's triad: the occurrence of hypoglycemic symptoms associated with blood glucose of \<54 mg/dL, and resolution with glucose or carbohydrate administration. Symptoms associated with reactive hypoglycemia include neuroglycopenic symptoms (e.g., behavioral changes, confusion or impaired cognitive function, seizure, loss of consciousness).
Willing and able to give informed consent and follow all study procedures and requirements.
Participants (male and female) must agree to use an adequate method of contraception
Has recurrent hypoglycemia of at least 4 episodes during a 3-week Run-In period.

Exclusion Criteria

History of current medical conditions excluding PBH which may result in hypoglycemia).
Current use of insulin or insulin secretagogues.
Current use of GLP-1 agonists, GLP-1/GIP dual agonists, or GLP-1 antagonists. Unless participants have been through a 'wash-out' period
Current use of drugs that may affect CGM function (e.g., acetaminophen/paracetamol).
History of recent fasting hypoglycemia.
Participants with rectal prolapse or pelvic floor dysfunction within 6 months of Screening.
Congestive heart failure, New York Heart Association class II, III or IV within 6 months of Screening.
History of myocardial infarction, unstable angina, or revascularization within 6 months of Screening.
History of a cerebrovascular accident within 6 months of Screening.
Active malignancy, except basal cell or squamous cell skin cancers.
Major surgical operation within 30 days of Screening.
Active alcohol abuse or substance abuse.
Pregnancy and/or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 2 weeks after participating in the study.
Other participants considered by the investigator to be inappropriate.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07760961) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Postbariatric Hypoglycemia Treatment Options in Nashville, TN

If you're searching for postbariatric hypoglycemia treatment options in Nashville, TN, this clinical trial (NCT07760961) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced postbariatric hypoglycemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all postbariatric hypoglycemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Nashville, TN

See all heart attack clinical trials recruiting in Nashville — not just this study.

Browse Heart Attack Trials in Nashville →

Browse More Trials by Condition

Heart Attack TrialsTuberculosis TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN